Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective, Single Center, Real-World Study Assessing Weight Changes in HIV-Positive Patients Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide Fumarate (TAF) Containing Treatment Regimen

Next Previous
Search
Trial Profile

A Retrospective, Single Center, Real-World Study Assessing Weight Changes in HIV-Positive Patients Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide Fumarate (TAF) Containing Treatment Regimen

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms 17-602

Most Recent Events

  • 09 Oct 2018 New trial record
  • 29 Sep 2018 Results published in the Infection Journal.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top